ClinicalTrials.gg
CompletedNCT02427958Updated Mar 16, 2022Results posted

A Study to Assess the Safety and Efficacy of Leuprorelin in Central Precocious Puberty in Chinese Participants

A Phase 4 interventional study of Leuprorelin in Central Precocious Puberty, sponsored by Takeda. Completed at 9 sites in China. Open to participants aged 1 Year to 9 Years. Per ClinicalTrials.gov, last updated 2022-03-16.

Sponsored by Takeda · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
307
Allocation
Not applicable
Ages
1 Year to 9 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 14 studies testing leuprolide in Puberty, Precocious — 2 open to participants now, 2 under way, 1 of them phase 3. Leuprolide · Puberty, Precocious.

Enrollment
2nd of 14
307 · median 68
Started
2015
with 1 other
Phase 4
5 of 14
1 open now
Registered
6th of 14
by date
Lead sponsor
1 of 14
Takeda

Among the 14 studies testing leuprolide in Puberty, Precocious, this one is the 2nd largest by enrollment, is one of 2 that started in 2015, is one of 5 in phase 4, and was the 6th registered.

Puberty, Precocious

75 studies on the registry are indexed under Puberty, Precocious; 18 are open to participants now.

Browse Puberty, Precocious studies →

Open to participants now

2 of the 14 studies testing leuprolide in Puberty, Precocious are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About leuprolide

Leuprolide: first FDA approval 1985 (LUPRON), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 14 Puberty, Precocious studies recruiting now, 2 (14%) set no upper age limit and 9 (64%) stop at 75 or younger; 14 take children under 18; 2 take healthy volunteers.

This study: 1 Year to 9 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing leuprolide in Puberty, Precocious, or all of them as a file.
02

Study summary

The purpose of this study is to assess long-term safety and efficacy of leuprorelin in the treatment of Central Precocious Puberty (CPP).

Read the detailed description

The drug in this study is called leuprorelin. It is administered as a 1 month subcutaneous depot injection. Leuprorelin is used to treat children who have CPP. This study will look at whether leuprorelin can stop early puberty in pre-pubertal children.

The study will enroll approximately 300 participants. Participants with body weight >=20 kg will receive the recommended dose of leuprorelin 3.75 mg subcutaneous injection every 4 weeks for 96 weeks. Participants with body weight \<20 kg will receive recommended dose of 1.88 mg subcutaneous injection every 4 weeks for 96 weeks.

This trial will be conducted in China. The overall time to participate in this study is 104 weeks. Participants will make 11 visits to the clinic, and will be followed-up by the physician on a long-term basis until stable puberty is reached.

03

Conditions studied

  • Central Precocious Puberty

Browse trials for

Keywords

  • Drug Therapy
04

Who can participate

Ages eligible
1 Year to 9 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. In the opinion of the investigator, the participant and/or parent(s) or legal guardian are capable of understanding and complying with protocol requirements.
  2. The participant or the participant's parent(s) or legally acceptable representative signs and dates a written, form and any required privacy authorization prior to the initiation of any study procedures.
  3. Has onset of appearance of secondary sexual characteristic earlier than age 8.0 years in girls or earlier than 9.0 years in boys and the symptom is persistent, and has confirmed diagnosis of CPP.
  4. Has basal luteinizing hormone (LH) level greater than (>) 5.0 international units per liter (IU/L) or peak LH >3.3 IU/L with LH/follicle-stimulating factor (FSH) >0.6 in stimulation test.
  5. Has evidence of gonadal development evaluated by ultrasonography: ovarian volume >=1 milliliter (mL) with multiple follicles >=4 millimeter (mm) in any ovary or uterine enlargement in females or testicular volume >=4 mL in males.
  6. Has advanced bone age (BA) >=1 year and BA is less than or equal to (\<=) 11.5 years in females or \<=12.5 years in males OR predicted adult height \<150 centimeter (cm) in females or \<160 cm in males OR standard deviation score (SDS) \<-2 standard deviations (SD) OR rapid growth defined as growth of BA /growth of chronologic age >1. BA is determined by Greulich and Pyle standards or Tanner-Whitehouse 3 (TW3) standards at screening.
  7. Has anticipated treatment duration of at least 2 year in investigator's judgment.
  8. A male participant who is nonsterilized and sexually active with a female partner of agrees to use adequate from signing of informed consent throughout the duration of the study and for 90 days after last dose.
  9. A female participant of childbearing potential who is sexually active with a nonsterilized male partner agrees to use routinely adequate contraception from signing of informed consent throughout the duration of the study.
  10. The female participant who, at the discretion of the investigator, is deemed to be of child bearing potential must provide negative urine pregnancy text at Day -1 or Day 1 prior to drug administration.

Exclusion criteria

Exclusion Criteria:

  1. Has received any compound within 30 days prior to Screening.
  2. Has received gonadotropin-releasing hormone analog (GnRHa) treatment in a previous clinical study or as a therapeutic agent.
  3. Is an immediate family member, study site employee, or is in a dependent relationship with a study site employee who is involved in the conduct of this study (example [eg], spouse, parent, child, sibling) or may consent under duress.
  4. Has any findings in his/her medical history, physical examination, or safety clinical laboratory tests giving reasonable suspicion of underlying disease that might interfere with the conduct of the trial.
  5. Has any concomitant medical condition that, in the opinion of the investigator, may expose a participant to an unacceptable level of safety risk or that affects participant compliance.
  6. Has any screening abnormal laboratory value that suggests a underlying disease or condition that may prevent the participant from entering the study; or the participant has: creatinine >=1.5 milligram per deciliter (mg/dL), (ALT) and/or aspartate aminotransferase (AST) >2 times the (ULN), or total >2.0 mg/dL, with AST/ALT elevated above the limits of normal values.
  7. Has a history or clinical manifestations of significant adrenal or thyroid diseases or intracranial tumor OR has a history of malignant disease.
  8. Has a history of or allergies to leuprorelin, or related compounds including any of the compound.
  9. Has a diagnosis of peripheral precocious puberty.
  10. Has a history of drug abuse (defined as any illicit drug use) or a history of alcohol abuse within 1 year prior to the Screening Visit.
  11. Participant or parent(s), at the discretion of the investigator, is unlikely to comply with the protocol or is unsuitable for any of other reason.
  12. If female, the participant is of (eg, not sterilized).
  13. If female, the participant is pregnant or lactating or intending to become pregnant before, during, or within 1 month after participating in this study; or intending to donate ova during such time period.
  14. If male, the participant intends to donate sperm during the course of this study or for 90 days thereafter.
  15. Has participated in another clinical study and/or has received any investigational compound within 30 days prior to Screening.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
307 participants (actual)

Study arms

  • Experimental
    Leuprorelin

    Participants with body weight greater than or equal to (\>=) 20 kilogram (kg) will receive the recommended dose of leuprorelin 3.75 milligram (mg), injection, subcutaneously, once every 4 weeks for 96 weeks. Participants with body weight less than (\<) 20 kg will receive leuprorelin 1.88 mg, injection, subcutaneously, once every 4 weeks for 96 weeks.

    Drug: Leuprorelin

Interventions

  • Suspension for injection.

    Also known as: Enantone

06

What researchers measure

Primary outcomes

  1. Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs)

    Time frame: Day 1 up to Week 100

Secondary outcomes

  1. Percentage of Participants With Regression or no Progression in Tanner Staging at Week 96

    Tanner assessment score was used to document the stage of development of puberty through the assessment of secondary sexual characteristics. Female pubertal development staged by pubic hair development and breast size; male pubertal development staged by size of the genitalia and development of pubic hair. Rated in 5 stages: stage 1 (no development) to 5 (adult-like development in quantity and size). Regression or no progression was defined as negative change (improvement) or no change in Tanner score at Week 96 compared to baseline.

    Time frame: Week 96

07

Results

Posted Jul 24, 2019

Participant flow

Participants took part in the study at 11 investigative sites in China from 07 August 2015 to 23 November 2018.

Participant flow — Overall Study
MilestoneLeuprorelin
Started307
Completed283
Not completed24
Withdrew: Pretreatment event (pte) or ae3
Withdrew: Lost to follow-up6
Withdrew: Withdrawal by subject14
Withdrew: Lack of efficacy1

Outcome measures

PrimaryNumber of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs)
Time frame:
Day 1 up to Week 100
Reported as:
Number · participants
Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs)
participantsLeuprorelin
Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs)252
SecondaryPercentage of Participants With Regression or no Progression in Tanner Staging at Week 96

Tanner assessment score was used to document the stage of development of puberty through the assessment of secondary sexual characteristics. Female pubertal development staged by pubic hair development and breast size; male pubertal development staged by size of the genitalia and development of pubic hair. Rated in 5 stages: stage 1 (no development) to 5 (adult-like development in quantity and size). Regression or no progression was defined as negative change (improvement) or no change in Tanner score at Week 96 compared to baseline.

Time frame:
Week 96
Reported as:
Number · percentage of participants
Percentage of Participants With Regression or no Progression in Tanner Staging at Week 96
percentage of participantsLeuprorelin
Female83.5 (78.68 to 87.62)
Male0 (0 to 84.19)

Adverse events

Collected over Treatment-emergent adverse events are adverse events that started after the first dose of study drug and no more than 30 days (Week 100) after the last dose of study drug. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Leuprorelin0/307 (0%)12/307 (3.9%)189/307 (61.6%)
Most frequent serious events
Showing 10 of 15
Most frequent serious events
EventLeuprorelin
PneumoniaInfections and infestations4/307
Pneumonia mycoplasmalInfections and infestations2/307
TonsillitisInfections and infestations2/307
AppendicitisInfections and infestations1/307
BronchitisInfections and infestations1/307
Chronic tonsillitisInfections and infestations1/307
Otitis mediaInfections and infestations1/307
Comminuted fractureInjury, poisoning and procedural complications1/307
Epiphyseal injuryInjury, poisoning and procedural complications1/307
Peripheral nerve injuryInjury, poisoning and procedural complications1/307
Most frequent other events
Most frequent other events
EventLeuprorelin
Upper respiratory tract infectionInfections and infestations118/307
CoughRespiratory, thoracic and mediastinal disorders51/307
PyrexiaGeneral disorders45/307
NasopharyngitisInfections and infestations35/307
BronchitisInfections and infestations34/307
TonsillitisInfections and infestations19/307
PharyngitisInfections and infestations16/307

Baseline characteristics

The safety analysis set included all enrolled participants who received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)Leuprorelin
Mean8.03 ± 0.935
Sex: Female, Male
Sex: Female, Male(Participants)Leuprorelin
Female305
Male2
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Leuprorelin
American Indian or Alaska Native0
Asian307
Native Hawaiian or Other Pacific Islander0
Black or African American0
White0
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(Participants)Leuprorelin
China307
Height
Height(centimeter (cm))Leuprorelin
Mean133.68 ± 7.108
Weight
Weight(kilogram (kg))Leuprorelin
Mean30.44 ± 5.346
Weight Categories
Weight Categories(Participants)Leuprorelin
<20 kg5
>=20 kg302
Age at date of diagnosis of CPP
Age at date of diagnosis of CPP(years)Leuprorelin
Mean7.95 ± 0.982

6 further baseline measures are reported on the registry.

08

Study locations

9 sites
  • Beijing, Beijing, China
  • Wuhan, Hubei, China
  • Changsha, Hunan, China
  • Nanjing, Jiangsu, China
  • Wuxi, Jiangsu, China
  • Nanchang, Jiangxi, China
  • Changchun, Jilin, China
  • Shanghai, Shanghai, China
  • Hangzhou, Zhejiang, China
09

References and documents

Publications

  • Luo X, Hou L, Zhong Y, You C, Yang Y, Wu X, Li P, Zhou S, Qiu W, Zhang H, Liu Y, Qian Y, Luo F, Cheng R, Hu Y, Gong H, Wang Q, Xu Z, Du H, Lu F, Fu J, Chen X, Wang W, Guo Z. An open label, multicenter clinical trial that investigated the efficacy and safety of leuprorelin treatment of central precocious puberty in Chinese children. Medicine (Baltimore). 2021 Dec 23;100(51):e28158. doi: 10.1097/MD.0000000000028158. PubMed 34941067 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/ For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2015 to primary completion in Nov 2018, 39 months.

Results were first posted in Jul 2019, 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 23, 2015
First posted
Apr 28, 2015
StartActual
Aug 7, 2015
Primary completionActual
Nov 23, 2018
CompletionActual
Nov 23, 2018
Results first posted
Jul 24, 2019
Last update
Mar 16, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 16, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02427958
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Apr 28, 2015
Start date
Aug 7, 2015
Primary completion
Nov 23, 2018
Completion
Nov 23, 2018
Results posted
Jul 24, 2019
Last update
Mar 16, 2022

Study contacts

Medical Director
study director · Takeda

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Leuprolide

Start the discussion